Chemical structure-related drug-like criteria of global approved drugs

Molecules

Volumn 21, Issue 1, 2016, Pages

  Mao, Fei ^a   Ni, Wei ^a   Xu, Xiang ^a   Wang, Hui ^a   Wang, Jing ^a   Ji, Min ^a   Li, Jian ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemical structure related criteria; Drug design; Drug like property; Functional group; Ring system; The heavy atoms proportion

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; NEUROPROTECTIVE AGENT; NEW DRUG;

CHEMICAL STRUCTURE; CHEMISTRY; DRUG APPROVAL; DRUG DATABASE; DRUG DESIGN; HUMAN; ORAL DRUG ADMINISTRATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR AGENTS; DATABASES, PHARMACEUTICAL; DRUG APPROVAL; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85000366430     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21010075     Document Type: Article

References (46)

1. Price Waterhouse Coopers (PWC). From Vision to Decision. Pharma 2020 Report; PWC: London, UK, 2012; Available online: http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/pharma-2020/vision-to-decision.html (accessed on 16 November 2015).
2. Sugiyama, Y. Druggability: Selecting optimized drug candidates. Drug Discov. Today 2005, 10, 1577-1579. [CrossRef].
3. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. 2000, 44, 235-249. [CrossRef].
4. Borchardt, R.T. Pharmaceutical Profiling in Drug Discovery for Lead Selection; American Association of Pharmaceutical Scientists: Arlington, VA, USA, 2004.
5. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliver. Rev. 1997, 23, 3-25. [CrossRef].
6. Veber, D.F.; Johnson, S.R.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623. [CrossRef] [PubMed].
7. Leeson, P.D.; Davis, A.M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 2004, 47, 6338-6348. [CrossRef] [PubMed].
8. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A rule of three for fragment-based lead discovery? Drug Discov. Today 2003, 8, 876-877. [CrossRef].
9. Wenlock, M.C.; Austin, R.P.; Barton, P.; Davis, A.M.; Leeson, P.D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46, 1250-1256. [CrossRef] [PubMed].
10. Manallack, D.T.; Prankerd, R.J.; Yuriev, E.; Oprea, T.I.; Chalmers, D.K. The significance of acid/base properties in drug discovery. Chem. Soc. Rev. 2013, 42, 485-496. [CrossRef] [PubMed].
11. Ellens, H.; Eddy, E.P.; Lee, C.-P.; Dougherty, P.; Lago, A.; Xiang, J.-N.; Elliott, J.D.; Cheng, H.-Y.; Ohlstein, E.; Smith, P.L. In vitro permeability screening for identification of orally bioavailable endothelin receptor antagonists. Adv. Drug Deliver. Rev. 1997, 23, 99-109. [CrossRef].
12. Pardridge, W.M. Transport of small molecules through the blood-brain barrier: Biology and methodology. Adv. Drug Deliv. Rev. 1995, 15, 5-36. [CrossRef].
13. Van De Waterbeemd, H.; Smith, D.A.; Beaumont, K.;Walker, D.K. Property-based design: Optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44, 1313-1333. [CrossRef] [PubMed].
14. Young, R.J.; Campbell, M.; Borthwick, A.D.; Brown, D.; Burns-Kurtis, C.L.; Chan, C.; Convery, M.A.; Crowe, M.C.; Dayal, S.; Diallo, H.; et al. Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. Bioorg. Med. Chem. Lett. 2006, 16, 5953-5957. [CrossRef] [PubMed].
15. Young, R.J.; Borthwick, A.D.; Brown, D.; Burns-Kurtis, C.L.; Campbell, M.; Chan, C.; Charbaut, M.; Chung, C.W.; Convery, M.A.; Kelly, H.A.; et al. Structure and property based design of factor Xa inhibitors: Pyrrolidin-2-ones with biaryl P4 motifs. Bioorg. Med. Chem. Lett. 2008, 18, 23-27. [CrossRef] [PubMed].
16. Eljack, F.T.; Eden, M.R.; Kazantzi, V.; Qin, X.Y.; El-Halwagi, M.A. Simultaneous process and molecular design-A property based approach. Aiche J. 2007, 53, 1232-1239.
17. Jiang, H.; Zuo, Y.; Zhang, L.; Li, J.D.; Zhang, A.M.; Li, Y.B.; Yang, X.C. Property-based design: Optimization and characterization of polyvinyl alcohol (PVA) hydrogel and PVA-matrix composite for artificial cornea. J. Mater. Sci. Mater. Med. 2014, 25, 941-952. [CrossRef] [PubMed].
18. Dowling, J.E.; Alimzhanov, M.; Bao, L.; Block, M.H.; Chuaqui, C.; Cooke, E.L.; Denz, C.R.; Hird, A.; Huang, S.; Larsen, N.A.; et al. Structure and property based design of pyrazolo 1, 5-a pyrimidine Inhibitors of CK2 kinase with activity in vivo. ACS Med. Chem. Lett. 2013, 4, 800-805. [CrossRef] [PubMed].
19. Larsen, S.D.;Wilson, M.W.; Abe, A.; Shu, L.M.; George, C.H.; Kirchhoff, P.; Showalter, H.D.H.; Xiang, J.M.; Keep, R.F.; Shayman, J.A. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J. Lipid Res. 2012, 53, 282-291. [CrossRef] [PubMed].
20. Fraley, M.E.; Hoffman, W.F.; Arrington, K.L.; Hungate, R.W.; Hartman, G.D.; McFall, R.C.; Coll, K.E.; Rickert, K.; Thomas, K.A.; McGaughey, G.B. Property-based design of KDR kinase inhibitors. Curr. Med. Chem. 2004, 11, 709-719. [CrossRef] [PubMed].
21. Balakin, K.V.; Tkachenko, S.E.; Lang, S.A.; Okun, I.; Ivashchenko, A.A.; Savchuk, N.P. Property-based design of GPCR-targeted library. J. Chem. Inf. Comp. Sci. 2002, 42, 1332-1342. [CrossRef].
22. Abraham, M.H.; Ibrahim, A.; Zissimos, A.M.; Zhao, Y.H.; Comer, J.; Reynolds, D.P. Application of hydrogen bonding calculations in property based drug design. Drug Discov. Today 2002, 7, 1056-1063. [CrossRef].
23. Kerns, E.H.; Di, L. Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization; Elsevier Inc.: Amsterdam, The Netherlands, 2008.
24. Bemis, G.W.; Murcko, M.A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893. [CrossRef] [PubMed].
25. Bemis, G.W.; Murcko, M.A. Properties of known drugs. 2. Side chains. J. Med. Chem. 1999, 42, 5095-5099. [CrossRef] [PubMed].
26. Ghose, A.K.; Viswanadhan, V.N.; Wendoloski, J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1999, 1, 55-68. [CrossRef] [PubMed].
27. Zheng, S.X.; Luo, X.M.; Chen, G.; Zhu, W.L.; Shen, J.H.; Chen, K.X.; Jiang, H.L. A new rapid and effective chemistry space filter in recognizing a druglike database. J. Chem. Inf. Model. 2005, 45, 856-862. [CrossRef] [PubMed].
28. Ritchie, T.J.; Macdonald, S.J.F. The impact of aromatic ring count on compound developability-Are too many aromatic rings a liability in drug design? Drug Discov. Today 2009, 14, 1011-1020. [CrossRef] [PubMed].
29. Ritchie, T.J.; Macdonald, S.J.; Young, R.J.; Pickett, S.D. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov. Today 2011, 16, 164-171. [CrossRef] [PubMed].
30. Ritchie, T.J.; Macdonald, S.J.F.; Peace, S.; Pickett, S.D.; Luscombe, C.N. The developability of heteroaromatic and heteroaliphatic rings-Do some have a better pedigree as potential drug molecules than others? Med Chem Comm 2012, 3, 1062. [CrossRef].
31. Ward, S.E.; Beswick, P. What does the aromatic ring number mean for drug design? Expert Opin. Drug Dis. 2014, 9, 995-1003. [CrossRef] [PubMed].
32. Taylor, R.D.; MacCoss, M.; Lawson, A.D. Rings in drugs. J. Med. Chem. 2014, 57, 5845-5859. [CrossRef] [PubMed].
33. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J. Med. Chem. 2014, 57, 10257-10274. [CrossRef] [PubMed].
34. Mirza, A.; Desai, R.; Reynisson, J. Known drug space as a metric in exploring the boundaries of drug-like chemical space. Eur. J. Med. Chem. 2009, 44, 5006-5011. [CrossRef] [PubMed].
35. Purser, S.; Moore, P.R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. Chem. Soc. Rev. 2008, 37, 320-330. [CrossRef] [PubMed].
36. Begue, J.P.; Bonnet-Delpon, D. Why fluorine is an invaluable tool in medicinal chemistry. Chim. Oggi. 2005, 23, 3-5.
37. Shah, P.; Westwell, A.D. The role of fluorine in medicinal chemistry. J. Enzym. Inhib. Med. Chem. 2007, 22, 527-540. [CrossRef] [PubMed].
38. Kirk, K.L. Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules. J. Fluorine Chem. 2006, 127, 1013-1029. [CrossRef].
39. Smith, B.R.; Eastman, C.M.; Njardarson, J.T. Beyond C, H, O, and N! analysis of the elemental composition of U.S. FDA approved drug architectures. J. Med. Chem. 2014, 57, 9764-9773. [CrossRef] [PubMed].
40. Ilardi, E.A.; Vitaku, E.; Njardarson, J.T. Data-mining for sulfur and fluorine: An evaluation of pharmaceuticals to reveal opportunities for drug design and discovery. J. Med. Chem. 2014, 57, 2832-2842. [CrossRef] [PubMed].
41. Chong, C.R.; Sullivan, D.J. New uses for old drugs. Nature 2007, 448, 645-646. [CrossRef] [PubMed].
42. Sci Finder. Available online: https://scifinder.cas.org (accessed on 17 November 2015).
43. DrugBank Database. Available online: http://Www.Drugbank.Ca (accessed on 17 November 2015).
44. Thomson Reuters Integrity. Available online: https://integrity.thomson-pharma.com (accessed on 17 November 2015).
45. Thomson Reuters Cortellis. Available online: https://cortellis.thomsonreuterslifesciences.com (accessed on 17 November 2015).
46. Reichel, A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr. Drug Metab. 2006, 7, 183-203. [CrossRef] [PubMed].